ReviewDiagnostics (Basel, Switzerland)2015
Imaging of HCC-Current State of the Art.
Review in Diagnostics (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Diagnosis of hepatocellular carcinoma using liquid biopsy-based biomarkers: a systematic review and network meta-analysis.Frontiers in oncology · 2024Pooled it
- Hepatocellular carcinoma in a child with hereditary tyrosinemia type I despite early NTBC therapy: When should we suspect it?Radiology case reports · 2026Article
- Revolutionizing early HCC detection: groundbreaking validation of the HCC-check index for small tumors in Egyptian patients using CLIP and BCLC staging systems.Medical oncology (Northwood, London, England) · 2025Article
- Bibliometrics and scientometrics analysis of exosomes relevance in hepatocellular carcinoma (2014-2024).Frontiers in oncology · 2025Review
- Article
- Potential diagnostic value of high b-value computed diffusion-weighted imaging in hepatocellular carcinoma.Clinical and experimental hepatology · 2024Article
- Role of exosomes in the development, diagnosis, prognosis and treatment of hepatocellular carcinoma.Molecular medicine (Cambridge, Mass.) · 2023Review
- Exosome Cargos as Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma.Pharmaceutics · 2023Review
- Application of artificial intelligence in the diagnosis of hepatocellular carcinoma.eGastroenterology · 2023Review
- Interpretation of Farnesoid X Receptor Immunohistochemical Expression in Discriminating Hepatocellular Carcinoma from Its Non-Neoplastic Mimics as an Adjunct to Glypican 3.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- The mesenchymal circulating tumor cells as biomarker for prognosis prediction and supervision in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Tumor-derived proliferative CTCs and CTC clusters predict aggressiveness and early recurrence in hepatocellular carcinoma patients.Cancer medicine · 2023Article
- Primary Tumor Radiomic Model for Identifying Extrahepatic Metastasis of Hepatocellular Carcinoma Based on Contrast Enhanced Computed Tomography.Diagnostics (Basel, Switzerland) · 2022Article
- Multi-detector computed tomography evaluation of synchronous hepatocellular carcinoma and other solid malignancies.Clinical and experimental hepatology · 2022Article
- Review
- Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma.Frontiers in oncology · 2022Review
- CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation.Cardiovascular and interventional radiology · 2021Article
- Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma.Infectious agents and cancer · 2021Review
- Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Circular RNA 0006602 in plasma exosomes: a new potential diagnostic biomarker for hepatocellular carcinoma.American journal of translational research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of hepatocellular carcinoma (HCC) is crucial for optimizing treatment outcome. Ongoing advances are being made in imaging of HCC regarding detection, grading, staging, and also treatment monitoring. This review gives an overview of the current international guidelines for diagnosing HCC and their discrepancies as well as critically summarizes the role of magnetic resonance imaging (MRI) and computed tomography (CT) techniques for imaging in HCC. The diagnostic performance of MRI with nonspecific and hepatobililiary contrast agents and the role of functional imaging with diffusion-weighted imaging will be discussed. On the other hand, CT as a fast, cheap and easily accessible imaging modality plays a major role in the clinical routine work-up of HCC. Technical advances in CT, such as dual energy CT and volume perfusion CT, are currently being explored for improving detection, characterization and staging of HCC with promising results. Cone beam CT can provide a three-dimensional analysis of the liver with tumor and vessel characterization comparable to cross-sectional imaging so that this technique is gaining an increasing role in the peri-procedural imaging of HCC treated with interventional techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.